BMY 20862Alternative Names: BMS 183729
Latest Information Update: 23 Aug 1995
At a glance
- Originator Bristol-Myers Squibb
- Class Anti-ischaemics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 23 Aug 1995 Discontinued-Preclinical for Stroke in USA (Unknown route)